London
Roots Analysis has announced the
addition of “Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and
Finished Dosage Forms, 2020-2030”report to its list of offerings.
Manufacturing live
biotherapeutic products is both technically challenging and financially
demanding; as a result, innovator firms are becoming increasingly reliant on
contract service providers to access specialized facilities and optimize
overall costs.
To
order this 300+ page report, which features 140+ figures and 125+ tables,
please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Key market Insights
Over
25 players claim to provide microbiome-based live biotherapeutics contract manufacturing
More than 80% of the companies
engaged in this domain are mid-sized and large firms; examples of firms established in 2019 include Arranta Bio and BacThera
(a Lonza and Chr. Hansen joint venture). Further, nearly 50% of the CMOs
have established the necessary expertise for handling both anaerobic and
aerobic strains.
35+
manufacturing facilities focused on live biotherapeutics have been established worldwide
Majority
(~55%) of the manufacturing facilities are located in Europe, followed by North America. Prominent
manufacturing hubs in the Europe include (in decreasing order of number of
manufacturing facilities) the UK,
France, the Netherlands, Italy, Germany, Switzerland, and Sweden.
Approximately
88% of the total installed capacity is dedicated to commercial scale
manufacturing
Whereas, rest (~10%) of the capacity is being used for preclinical / clinical
scale manufacturing of microbiome products. In addition, over 60% of the total
current global, installed manufacturing capacity is installed in Europe.
Over
170 registered clinical trials involved the use of microbiome-based live
biotherapeutics
Majority
of these studies are being conducted at various hospitals / centers across the
US. Examples of leading non-industry players include (in decreasing order of
number of trials) University of California, National Institute of Allergy
and Infectious Diseases, Radboud University, and The University of Texas Health
Science Center.
The global clinical demand
for microbiome-based live biotherapeutic products is anticipated to grow at a CAGR of 23%,
between 2020 and 2030
By
2030, over 31,000 patients are estimated to be enrolled in the clinical trials
involving the use of microbiome-based live biotherapeutics. Industry players
are anticipated to contribute majority (over 60%) of the demand in the
short-term as well as long-term.
Several
big pharma players are actively engaged in the microbiome live biotherapeutics
domain
In
fact, leading pharmaceutical companies have partnered with smaller business
entities to develop manufacturing capabilities related to microbiome-based
therapies / diagnostics. Examples of such small ventures with players with
in-house capability include (in alphabetical order) Assembly
Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.
By 2030, North America and Europe are anticipated to
capture over 85% of the market opportunity
In
terms of type of product manufactured, APIs currently represent the highest
share (58%); this trend is unlikely to change in the foreseen future.
To request a sample
copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/281/request-sample.html
Key
Questions Answered
§ Who
are the leading CMOs offering microbiome contract manufacturing services,
across the world?
§ What
are the key challenges faced by microbiome contract manufacturers?
§ What
is the annual clinical demand for microbiome-based live biotherapeutic products?
§ What is the current, installed contract
manufacturing capacity for live biotherapeutics?
§ What
are the key factors influencing the make (manufacture in-house) versus
buy (outsource) decision in this field?
§ What
are the various initiatives undertaken by big pharma players in this domain?
§ What
percentage of live biotherapeutics manufacturing
operations are outsourced to service providers?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
§ What are the anticipated future trends related to live biotherapeutics manufacturing?
The USD 300 million (by 2030) financial opportunity
within the microbiome contract manufacturing market has been analysed across
the following segments:
§ Type
of Product Manufactured
§ Active
Pharmaceutical Ingredients (APIs)
§ Finish
Drug Formulations (FDFs)
§ Type
of Type of Formulation
§ Solid
Formulations
§ Oral
Liquids
§ Injectables
§ Others
§ Scale
of Operation
§ Clinical
§ Commercial
§ Company
Size
§ Small-sized
§ Mid-sized
§ Large
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
and Rest of the World
The
research covers detailed profiles brief profiles of several companies (including
those listed below); each profile features an overview of the company, its
financial information (if available),
microbiome-related service portfolio, facilities dedicated to microbiome
manufacturing, and an informed future outlook.
§ Biose®
§ BJP
Laboratories
§ Capsugel
(acquired by Lonza)
§ Cerbios-Pharma
§ Cobra
Biologics (acquired Cognate Bioservices)
§ Inpac
Probiotics
§ Paragon Bioservices (a unit of Catalent Biologics)
§ UAS
Labs
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd
Edition), 2020-2030
2. Antibody Contract Manufacturing Market, 2020 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis